Loading...
XNASTXG
Market cap1.89bUSD
Jan 10, Last price  
15.58USD
1D
-1.58%
1Q
-4.18%
IPO
-70.19%
Name

10X Genomics Inc

Chart & Performance

D1W1MN
XNAS:TXG chart
P/E
P/S
3.05
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
54.31%
Rev. gr., 5y
33.43%
Revenues
619m
+19.81%
71,085,000146,313,000245,893,000298,845,000490,490,000516,409,000618,727,000
Net income
-255m
L+53.67%
-18,762,000-112,485,000-31,251,000-542,731,000-58,223,000-166,000,000-255,099,000
CFO
-15m
L-54.78%
-10,699,000-76,409,00034,627,000-217,898,000-21,373,000-33,606,000-15,197,000
Earnings
Feb 13, 2025

Profile

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
IPO date
Sep 12, 2019
Employees
1,243
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
618,727
19.81%
516,409
5.28%
Cost of revenue
823,076
684,353
Unusual Expense (Income)
NOPBT
(204,349)
(167,944)
NOPBT Margin
Operating Taxes
6,336
4,029
Tax Rate
NOPAT
(210,685)
(171,973)
Net income
(255,099)
53.67%
(166,000)
185.11%
Dividends
Dividend yield
Proceeds from repurchase of equity
19,483
21,226
BB yield
-0.30%
-0.51%
Debt
Debt current
23,042
9,037
Long-term debt
263,068
181,315
Deferred revenue
8,814
3,165
Other long-term liabilities
(79,574)
6,141
Net debt
(102,585)
(244,606)
Cash flow
Cash from operating activities
(15,197)
(33,606)
CAPEX
(48,601)
(131,661)
Cash from investing activities
133,492
(350,887)
Cash from financing activities
13,669
15,817
FCF
(224,165)
(326,353)
Balance
Cash
388,695
429,984
Long term investments
4,974
Excess cash
357,759
409,138
Stockholders' equity
(1,284,847)
(1,033,654)
Invested Capital
2,229,719
1,939,800
ROIC
ROCE
EV
Common stock shares outstanding
117,165
113,859
Price
55.96
53.57%
36.44
-75.54%
Market cap
6,556,555
58.03%
4,149,010
-74.76%
EV
6,453,970
3,904,404
EBITDA
(160,730)
(134,938)
EV/EBITDA
Interest
33
476
Interest/NOPBT